1,181,413 Shares in ProQR Therapeutics (NASDAQ:PRQR) Acquired by ArrowMark Colorado Holdings LLC

ArrowMark Colorado Holdings LLC acquired a new stake in shares of ProQR Therapeutics (NASDAQ:PRQR - Free Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 1,181,413 shares of the biopharmaceutical company's stock, valued at approximately $3,131,000. ArrowMark Colorado Holdings LLC owned 1.45% of ProQR Therapeutics at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Adage Capital Partners GP L.L.C. increased its holdings in ProQR Therapeutics by 164.9% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 9,602,280 shares of the biopharmaceutical company's stock valued at $25,446,000 after buying an additional 5,976,813 shares in the last quarter. Affinity Asset Advisors LLC acquired a new position in ProQR Therapeutics in the 4th quarter worth about $7,486,000. Platinum Investment Management Ltd. purchased a new position in ProQR Therapeutics during the fourth quarter worth approximately $4,076,000. Altium Capital Management LLC purchased a new stake in shares of ProQR Therapeutics in the fourth quarter valued at approximately $1,524,000. Finally, Walleye Capital LLC acquired a new position in shares of ProQR Therapeutics during the 4th quarter worth approximately $1,196,000. Institutional investors and hedge funds own 32.65% of the company's stock.

ProQR Therapeutics Price Performance

PRQR traded up $0.05 during trading hours on Friday, reaching $1.60. 197,166 shares of the stock traded hands, compared to its average volume of 617,031. The firm's fifty day simple moving average is $1.50 and its two-hundred day simple moving average is $2.42. The company has a market cap of $167.81 million, a price-to-earnings ratio of -4.98 and a beta of 0.35. ProQR Therapeutics has a fifty-two week low of $1.07 and a fifty-two week high of $4.62.

Analysts Set New Price Targets

Several equities research analysts have commented on PRQR shares. Oppenheimer initiated coverage on ProQR Therapeutics in a research note on Friday, January 10th. They set an "outperform" rating and a $15.00 price objective for the company. HC Wainwright boosted their price target on ProQR Therapeutics from $10.00 to $12.00 and gave the stock a "buy" rating in a research report on Friday, March 14th. Citigroup raised shares of ProQR Therapeutics from a "neutral" rating to a "buy" rating and set a $4.00 target price on the stock in a research note on Monday, March 10th. Cantor Fitzgerald started coverage on shares of ProQR Therapeutics in a research note on Tuesday, April 29th. They set an "overweight" rating and a $8.00 price objective for the company. Finally, Evercore ISI initiated coverage on shares of ProQR Therapeutics in a research note on Tuesday, April 29th. They issued an "outperform" rating and a $5.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $8.75.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).